Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Anticipate generic drug launch
|Title:||Phenoxy-hydroxypropylamines, method and pharmaceutical preparations for treating cardiovascular diseases|
|Abstract:||Para-substituted phenoxy-hydroxypropylamines having the general formula ##SPC1## And pharmaceutically acceptible, non-toxic acid addition salts thereof, wherein R is an isopropyl or tertiarybutyl radical; Z is a member selected from the group consisting of --OR", --SR", and --NHCOOR", R" being a straight or branched lower alkyl radical having 1 to 3 carbon atoms; and n is 1, 2, or 3, are disclosed as are methods for their preparation. Pharmaceutical preparations are prepared whose active ingredients include at least one of the newly discovered phenoxy-hydroxypropylamine compounds. Therapeutically effective does of these preparations selectively block the .beta.-receptors of the heart marking them useful in treating heart diseases in animals including humans.|
|Inventor(s):||Brandstrom; Arne Elof (S-415 06 Molnlycke, SW), Carlsson; Per Arvid Emil (S-413 19 Molnlycke, SW), Carlsson; Stig Ake Ingemar (S-435 00 Molnlycke, SW), Corrodi; Hans Rudolf (S-151 33 Sodertalje, SW), Ek; Lars (S-430 34 Onsala, SW), Ablad; Arne Hjalmar (S-411 28 Goteborg, SW)|
Patent Claim Types:|
see list of patent claims
|Use; Composition; Compound; Formulation; Dosage form;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.